AI-powered contentSome parts of this article are powered by AI.
Share this article
Gotrade News - ImmunityBio (IBRX) reported third-quarter 2026 net product revenue of $48.7 million, up 53% year-over-year, according to ImmunityBio's official release filed with the SEC on Monday, November 9, 2026. Net loss attributable to common stockholders was $184.6 million, compared with $67.3 million a year earlier.
Regular-session close on November 9, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com. Market cap: that close times the shares outstanding on the latest 10-Q or 10-K cover (SEC EDGAR).
ImmunityBio Earnings Details
Net product revenue increased $17.0 million in the three months ended September 30, 2026, compared with the same quarter of 2025, which the company attributed to an increase in sales of ANKTIVA, its immunotherapy for non-muscle invasive bladder cancer (NMIBC). For the first nine months of 2026, net product revenue totaled $143.6 million, up 92% from the first nine months of 2025, the release said.
Other expense, net rose to $106.6 million from $11.7 million a year earlier, primarily due to non-cash changes in the fair value of a related-party convertible note, warrant liabilities and other derivative liabilities, according to the company. Adjusted net loss attributable to common stockholders, a non-GAAP measure, was $97.9 million, compared with $72.4 million.
Research and development expense was $71.5 million, compared with $51.2 million, and selling, general and administrative expense was $54.0 million, compared with $36.3 million. The company held $334.3 million in cash and cash equivalents and marketable securities as of September 30, 2026.
Why It Matters for IBRX
The company reported the quarter alongside regulatory progress for ANKTIVA. On October 14, 2026, the FDA approved an expanded indication for ANKTIVA with BCG that includes adult patients with BCG-unresponsive NMIBC with high-grade papillary-only tumors. ImmunityBio also said Cohort A of its QUILT-2.005 trial in BCG-naïve NMIBC met its primary endpoint and that it remains on track to submit an sBLA in the fourth quarter of 2026. ANKTIVA is now approved or authorized in six regulatory jurisdictions covering 35 countries, the company said.
The nine-month figure builds on full-year 2025 net product revenue of $113.0 million, according to the release. "The recent label expansion represents an important opportunity to broaden access to ANKTIVA for a significantly larger patient population," said Richard Adcock, President and CEO of ImmunityBio.
This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.
This article was written with the help of AI and checked by the Gotrade team before publishing.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
M. Alfathan Rahman is a content writer with over 3 years of experience developing digital content strategies across various industries, including fintech. He has experience producing content for tax-related websites and financial education platforms. His focus areas include data research, and crafting financial articles that are informative, accurate, and accessible to investors of all experience levels.
